Quotes 5-day view Delayed Nasdaq
133 347 Volume
Estimated financial data (e) (USD)
Net income 2021
Net Debt 2021
P/E ratio 2021
Net income 2022
Net Debt 2022
P/E ratio 2022
Capi. / Sales 2021
Capi. / Sales 2022
Nbr of Employees
Eyenovia, Inc. is a clinical stage ophthalmic company. The company is developing a pipeline of therapeutics based microdose array print (MAP) platform technology. Its pipeline is focused on the late-stage development of microdosed medications for progressive myopia, presbyopia, and mydriasis. MydCombi is a combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye...
Ratings of Eyenovia, Inc.
All news about EYENOVIA, INC.
09/17 EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
09/17 Arctic Vision Announces Addition of Novel Mydriatic Drug MydcombiÖ to Eyenovi..
09/15 EYENOVIA : Material Definitive Agreement (Form 8-K)
09/15 EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
09/15 Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic..
08/12 EYENOVIA : Management's Discussion and Analysis of Financial Condition and Resul..
08/11 EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evalu..
08/11 EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Fi..
08/11 Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30,..
08/11 Eyenovia Reports Second Quarter 2021 Financial Results
08/04 Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11
07/19 EYENOVIA : to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
07/07 Eyenovia to Participate in Two Upcoming Investor Conferences
06/21 EYENOVIA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
06/16 EYENOVIA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
News in other languages on EYENOVIA, INC.
- No features available -
Analyst Recommendations on EYENOVIA, INC.
Technical analysis trends EYENOVIA, INC.
Short Term Mid-Term Long Term Trends Neutral Neutral Neutral
Number of Analysts
Last Close Price
Average target price
Spread / Average Target